Cognition Therapeutics
CGTX
35 hedge funds and large institutions have $13M invested in Cognition Therapeutics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
9% more funds holding
Funds holding: 32 → 35 (+3)
0.15% less ownership
Funds ownership: 24.4% → 24.25% (-0.15%)
6% less capital invested
Capital invested by funds: $13.8M → $13M (-$812K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$167K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$114K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53K |
| 4 |
BlackRock
New York
|
+$43.8K |
| 5 |
Bank of New York Mellon
New York
|
+$37.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
-$211K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$160K |
| 3 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
-$84.2K |
| 4 |
Two Sigma Investments
New York
|
-$55.9K |
| 5 |
Neuberger Berman Group
New York
|
-$31.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Charles Schwab
San Francisco,
California
| $21.9K | +$25.3K | +11,965 | New |
|
|
RCG
27
Rock Creek Group
Washington,
District of Columbia
| $18.7K | -$84.2K | -39,778 | -80% |
|
28
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $10.7K | – | – | – |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $7.8K | -$2.25K | -1,063 | -20% |
|
|
BCA
30
Bray Capital Advisors
Naples,
Florida
| $4.12K | – | – | – |
|
31
UBS Group
Zurich,
Switzerland
| $1.12K | +$1.29K | +610 | New |
|
32
Wells Fargo
San Francisco,
California
| $251 | +$28 | +13 | +10% |
|
33
JP Morgan Chase
New York
| $92 | +$106 | +50 | New |
|
34
Fidelity Investments
Boston,
Massachusetts
| $2 | – | – | – |
|
|
35
Two Sigma Investments
New York
| – | -$55.9K | -28,236 | Closed |
|
|
36
Neuberger Berman Group
New York
| – | -$31.4K | -15,884 | Closed |
|
|
DI
37
Diligent Investors
Redlands,
California
| – | -$19.8K | -10,000 | Closed |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$537 | +254 | New |
|
CGTX Hedge Fund Activity: Q2 2023 in Review
35 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q2 2023, worth a combined $13M — down 5.9% from $13.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CGTX positions and 3 closed out — a net gain of 3 holders — while 9 added to existing stakes and 8 trimmed.
The largest buyer was Kestra Advisory Services, adding an estimated $167K. The largest seller was Voss Capital, cutting an estimated $211K.
- 35 institutional investors held Cognition Therapeutics (CGTX) as of Q2 2023, up from 32 in Q1 2023.
- Funds reported $13M of Cognition Therapeutics stock for Q2 2023, down 5.9% quarter-over-quarter.
- 6 funds opened new Cognition Therapeutics positions in Q2 2023 and 3 closed out, a net change of +3 holders.
- The largest Cognition Therapeutics buyer in Q2 2023 was Kestra Advisory Services, an estimated $167K added.
- The largest Cognition Therapeutics seller in Q2 2023 was Voss Capital, an estimated $211K sold.
Based on aggregated 13F filings for Q2 2023.